How to Cite
Abstract
Currently there is no single approach to treatment for aggressive diffuse large-cell B-cell lymphoma (Double-HIT and Triple-HIT). Accumulated world data remain controversial and, given the unfavorable prognosis in this subgroup, high-dose chemotherapy with autologous stem cell transplantation in the first line of treatment is a therapeutic option.References
Bolanos-Meade J., Garrett-Mayer E., Luznik L. et al. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma // Biol. Blood. Marrow Transplant. -2007. - Vol. 10. - №13. - P. 1185 - 1191.
Greb A., Bohlius J., Schiefer D. et al. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults // PubMed Health. - 2010.
Linch D. C., Yung L., Smith P. et al. Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients №65 years with poor prognosis histologically aggressive NHL: research paper // British Journal of Haematology. - 2010. - Vol. 149. - № 2. - P. 237- 243.
Gunnellini М., Emili R., Coaccioli S. et al. The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma // Advances in Hematology. - 2011. - Vol. 2012.
Philip T, Guglielmi C., Hagenbeek A. et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma // New England Journal of Medicine. - 1995. - Vol. 333. - № 23. - P. 1540 - 1545.
Shipp M.A., Harrington D. P., Andersen J.R. et al. A predictive model for aggressive non-Hodgkin's lymphoma // New England Journal of Medicine. - 1993. - Vol. 329. - № 14. - P. 987-994.
Tilly H., Dreyling M. Di use large B-cell non-Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up // Annals of Oncology. - 2010. - Vol. 21. - № 5. - P. 172-174.
Ulrich J.M. Mey, Vandana Jha, John W. Strehl et al. High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma // GMS German Medical Science. - 2007. - Vol. 5. - P. 1612.
Yin J., Wei J., Xu J.H. et al. Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma: results of a comprehensive meta-analysis // Acta Haematol. - 2014. - Vol. 2. - № 131. - P. 114 - 125.
Adhikary S., Eilers M. Transcriptional regulation and transformation by Myc proteins // Nat. Rev. Mol. Cell Biol. - 2005. - Vol. 6. - P. 635-645.
Korsmeyer S.J. Bcl-2 initiates a new category of oncogenes: regulators of cell death // Blood. - 1992. -Vol. 80. - P. 879-886.
Phan R.T., Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells // Nature. - 2004. - Vol. 432. - P. 635-639.
Deborah M. Stephens, John W. Sweetenham. Clinical Controversies of Double-Hit Lymphoma // AJHO. - 2015. - Vol. 11. - № 4. - P. 10-16.
Sarkozy C., Traverse-Glehen A., Coiffier B. Double-hit and double-protein expressor lymphomas: agressive and refractory lymphomas// Lancet Oncol. - 2015. - Vol. 16 (15). - e555-67. - DOI: 10.1016/S1470-2045(15)00005-4
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2017